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Burkholderia pseudomallei and its close relative B. mallei are human pathogens that are classified as Tier 1
bio-threat agents. Both organisms have previously been shown to constitutively produce a capsular
polysaccharide (CPS) that is both a virulence determinant and protective antigen. Extraction and puri-
fication of CPS for use as a potential vaccine candidate requires containment level 3 laboratories which is
expensive and time-consuming. B. thailandensis strain E555 is closely related to B. pseudomallei and
B. mallei, but is non-pathogenic to humans and based on immunological cross-reactivity has previously
been shown to express a B. pseudomallei-like CPS. In this study, capsular polysaccharide isolated from an
O-antigen deficient strain of B. thailandensis E555 was identified by 1H and 13C NMR spectroscopy as -3-
)-2-O-acetyl-6-deoxy-b-D-manno-heptopyranose-(-1, and identical to that produced by B. pseudomallei.
This was further substantiated by anti-CPS monoclonal antibody binding. In connection with the pro-
duction of CPS fragments for use in glycoconjugate vaccines, we set out to assess the importance or
otherwise of the CPS 2-OAc groups in immune protection. To this end conjugates of the native and de-O-
acetylated CPS with the Hc fragment of tetanus toxin (TetHc) were used as vaccines in a mouse model of
melioidosis. The level of protection provided by deacetylated CPS was significantly lower than that from
native, acetylated CPS. In addition, sera from mice vaccinated with the deacetylated CPS conjugate did
not recognise native CPS. This suggests that CPS extracted from B. thailandensis can be used as antigen
and that the acetyl group is essential for protection.
Crown Copyright © 2017 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Content includes material subject to © Crown copyright (2017),
Dstl. This material is licensed under the terms of the Open Gov-
ernment Licence except where otherwise stated. To view this
licence, visit http://www.nationalarchives.gov.uk/doc/open-
government-licence/version/3 or þ write to the InformationBayliss), rob.field@jic.ac.uk
evier Ltd. This is an open access aPolicy Team, The National Archives, Kew, London TW9 4DU, or
email: psi@nationalarchives.gsi.gov.uk.
1. Introduction
Burkholderia pseudomallei is a tropical pathogen and the caus-
ative agent of melioidosis, which results in an estimated 90,000
human deaths per year [1,2]. Melioidosis can present itself in a
number of forms, ranging from acute pneumonia or septicaemia to
chronic infections characterised by abscess formation at multiple
sites on the body. Sub-clinical infections have also been reported
which may remain undiagnosed for a number of years [3,4]. Thisrticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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antibiotics, including penicillins, rapamycins, aminoglycosides and
third-generation cephalosporins [5]. B. mallei, a close relative of
B. pseudomallei, is the etiologic agent of glanders, a disease pri-
marily of horses and related solipeds, where it is associated with a
high mortality rate without antibiotic therapy [6]. Infection in
humans can be very severe and is characterised by extreme pain,
fever and abscesses primarily of the spleen and liver [7].
B. pseudomallei and B. mallei are classified as Tier 1 select agents by
the Department of Health and Human Services [8]; no vaccines are
available for either melioidosis or glanders.
Both B. pseudomallei and B. mallei organisms produce multiple
cell surface glycans, one of which is common to both species;
capsular polysaccharide (CPS) with the repeating homopolymer
structure based on -3)-2-O-acetyl-6-deoxy-b-D-manno-heptopyr-
anose-(1- [9]. CPS is one of the main surface-associated antigens of
B. pseudomallei and B. mallei [10], with anti-CPS antibodies
commonly present in convalescent patient antisera [11]. CPS is also
a known virulence determinant of both of these species, as loss of
capsule production results in strong attenuation in animal models
of disease [3,12]. CPS has also been demonstrated to be a protective
antigen in animal models against both B. pseudomallei and B. mallei
challenge; passive transfer of anti-CPS monoclonal antibody also
provides partial protection [13e15]. However, despite recent ad-
vances in methods for CPS purification from pathogenic Bur-
kholderia, [9] the yields are low and the requirement for high level
containment facilities when cultivating these organisms at scale is
problematic and costly. Several studies have, however, utilised the
6-deoxyheptan CPS extracted from non-pathogenic, select-agent
excluded strains of B. pseudomallei [16,17].
Burkholderia thailandensis is closely related to B. pseudomallei
and B. mallei, but with a >105-fold reduction in virulence, with
recent data suggesting that B. thailandensis lacks a critical patho-
genic activity common to B. mallei and B. pseudomallei [18,19]. As
B. thailandensis can be handled at lower levels of containment and
is very similar genetically to B. pseudomallei, it is often used as a
substitute in melioidosis research [4,20e22]. Althoughmost strains
of B. thailandensis do not produce CPS, the E555 strain produces a
polysaccharide that cross-reacts with an anti-B. pseudomallei CPS
monoclonal antibody [23]. In combination with the high sequence
similarity of six CPS genes between these two species [23], this
offers the potential for a source of CPS from an essentially avirulent
organism, which would be less expensive, quicker and safer to
produce. However, confirmation of its CPS structure is required.
Compared to non-pathogenic, select-agent excluded strains of
B. pseudomallei; B. thailandensis has the advantage of being a
naturally avirulent strain with no potential for reversion, which
may be more palatable for use in pharmaceutical scale-up.
Whilst extraction of CPS from avirulent B. thailandensis E555
would be an improvement over current methods, the CPS itself is
very much larger than carbohydrate antigens used in licensed
vaccines which utilise oligosaccharides, and is not ideal or optimal
for melioidosis glycoconjugate development considering the re-
ported success with a synthetic hexamer of 1524 Da [24]. The use of
short chain, oligosaccharide fragments of CPS would assist devel-
opment of a defined glycoconjugate and provide more vaccine
doses per mg of CPS extracted. While cutting-edge chemical syn-
thesis, including of a hexasaccharide fragment of CPS has recently
been reported [24,25], such approaches remain challenging at this
time. Plausible acid- or base-mediated conditions for partial
depolymerisation of native CPS give rise to de-O-acetylation (un-
published observations). If the 2-OAc group could be demonstrated
to have limited impact on vaccine efficacy, this would open up the
use of CPS hydrolysis fragments for glycoconjugate vaccine pro-
duction. A challenge to this prospect lies in recent work withsynthetic CPS fragments, which show that the 2-OAc group is
essential in the interaction with an anti-CPS monoclonal antibody;
absence of the acetyl moiety resulted in complete loss of antibody
affinity [26]. While this observation does not necessarily mean a
loss of immune protection as a result of CPS deacetylation, this
observation clearlymerits attention. In other systems, the impact of
polysaccharide antigen acetylation on immune responses is vari-
able and has had some impact on vaccine design [27e31]. In the
current study, we have investigated the structure of the CPS pro-
duced by B. thailandensis E555. Our studies have addressed the
immunogenicity and the protective potential of this material con-
jugated to the Hc fragment of tetanus toxin (TetHc), a carrier protein
used in previous work [24], in comparison to the corresponding
deacetylated CPS conjugate in a murine model of acute melioidosis.
2. Results
2.1. 6-Deoxy-D-manno-heptose
In support of analytical and structural studies on the
B. thailandensis E555 CPS, defined 6-deoxy-manno-heptose was
chemically synthesised. The synthetic route employed was essen-
tially that described by Aspinall et al. [32] In outline, this involved
C-6 extension of a suitably protected 6-deoxy-6-iodo-a-D-man-
nopyranoside with cyanide, followed by nitrile reduction-
hydrolysis-reduction, proceeding via imine and aldehyde in-
termediates. Final global deprotection afforded the desired
monosaccharide.
2.2. Extraction and structural characterisation of CPS from B.
thailandensis E555:: wbiI (pKnock-KmR)
Analysis of 1H NMR spectra of CPS extracted from
B. thailandensis E555:: wbiI (pKnock-KmR) demonstrated the
presence of essentially the same (1 / 3)-linked 2-O-acetyl-6-
deoxy-b-D-manno-heptopyranose repeat unit as found in CPS
extracted from B. pseudomallei strain 1026b (Fig. 1) and from
B. pseudomallei BP2683 [9]. Corresponding HSQC and 13C NMR data
(Figure S1 and S2 in supplementary information) also supported
that structure. An additional spin system (highlighted with aster-
isks in Fig. 1) present in CPS 1H NMR spectra can be identified as a
set of signals belonging to a-1,3-mannan, a polymer which is
known to be produced by B. pseudomallei and B. mallei strains and is
also present in purified B. thailandensis CPS [9]. Monosaccharide
analysis of fully hydrolysed CPS from B. thailandensis E555:: wbiI
(pKnock-KmR), using high-performance anion-exchange chroma-
tography with pulse amperometric detection (HPAEC-PAD) estab-
lished the presence of 6-deoxy-manno-heptose, which was
confirmed by spiking experiment of the hydrolysed sample with
defined 6-deoxy-manno-heptose (Fig. 2, peak B). Also identified
was D-mannopyranose (peak C) by co-injection of the sample with
D-mannose (data not shown).
To investigate any potential differences in CPS secondary
structure, the comparative binding of an anti-CPS monoclonal
antibody generated against heat-killed B. pseudomallei (DSTL189) to
both B. pseudomallei and B. thailandensis purified CPS samples was
assessed. There was no significant difference over a range of
B. pseudomallei 1026b and B. thailandensis E555:: wbiI (pKnock-
KmR) purified CPS concentrations (supplementary information,
Figure S3).
2.3. Role of the CPS 2-OAc group in antibody recognition
After confirmation of structural similarity between
B. thailandensis E555 and B. pseudomallei 1026b CPS by NMR and
Fig. 1. Carbohydrate regions of 1H NMR spectra (400 MHz, D2O, 25 C) of CPS isolated from (A) B. pseudomallei 1026b, (B) B. thailandensis E555:: wbiI (pKnock-KmR), and (C)
deacetylated CPS from B. thailandensis E555. Signals of a-1,3-mannan present in CPS spectra are is indicated by asterisks. Spectra of native CPS are recorded using water suppression
experiment.
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fluence of the acetyl moiety on CPS antibody recognition. Following
recent work which demonstrated the importance of CPS acetyla-
tion to antibody recognition [26], a sample of deAc CPS was pre-
pared by treatment of native CPS with aqueous ammonia. In these
mild conditions the main structure of CPS remains unaffected as
followed from monitoring the reaction by 1H NMR. Furthermore,
the 1H NMR spectrum of a product of deacetylation (Fig. 1C)
revealed a characteristic upfield shift of the resonance of H-2 and
disappearance of OAc signal confirming a complete removal of
acetyl group. Deacetylated CPS was probed with four anti-CPS
monoclonal antibodies (DSTL187, 188, 189, 190)13 and essentially
complete loss of antibody affinity to the deacetylated CPS was
apparent by ELISA (supplementary information, Figure S4).
2.4. Role of the CPS 2-OAc group in antibody elicitation and
immune protection
Whilst CPS is a promising vaccine candidate, polysaccharide
immunogenicity can be improved by conjugation to an appropriate
protein carrier, such as the Hc fragment of tetanus toxin [33]. Such
conjugates provide T-cell dependent immunogenicity, including
immunological memory, avidity maturation and isotype switching
to generate complement-activating antibody isotypes such as IgG1
[34]. In order to determine the effect of CPS acetylation on immune
protection against Burkholderia infection, glycoconjugate vaccines
were produced with carrier protein TetHc chemically conjugated by
reductive amination [16] to purified B. thailandensis E555:: wbiI
(pKnock-KmR) CPS or its deacetylated counterpart (deAc CPS),which other than the absence of the O-acetyl group had exactly the
same structure as native CPS (Fig. 1C). The glycoconjugate vaccines
were analysed by SDS-PAGE and western blot (supplementary
information, Figure S5-S6), and the ratio sugar: protein deter-
mined by phenol-sulfuric acid and BCA assays, respectively
(supplementary information, Table S1). BALB/c mice were vacci-
nated with native and deAc CPS-TetHc vaccines containing 10 mg of
CPS per dose on three occasions, 2 weeks apart, followed by a 5-
week rest period and then challenged intraperitoneally with
B. pseudomallei K96243 (1.17  105 CFU/mouse). There was a sta-
tistically significant difference in comparative efficacy between the
TetHc conjugates containing CPS or deAc CPS (p ¼ 0.0015, Fig. 3). In
addition, the protective efficacy of deAc CPS-TetHc was not signif-
icantly different to adjuvant alone (p ¼ 0.1694, Fig. 3).
Analysis of the relevant CPS-specific IgG and IgM titres from
mouse sera following the third vaccination showed an IgG and IgM
response in mice vaccinated with native CPS-TetHc and only an IgG
response in mice that received deAc CPS-TetHc. CPS-specific anti-
body responses in mice vaccinated with deAc CPS-TetHc were
significantly lower than mice that received native CPS-TetHc.
Analysis of the deAc CPS-specific antibody response showed a very
low IgG titre in native CPS-TetHc vaccinated mice which was
significantly lower than in mice that received deAc CPS-TetHc
(Fig. 4).
3. Discussion and conclusions
B. pseudomallei and its close relative B. mallei are Tier 1 select
agents due to the severity of disease, infection by the aerosol route,
Fig. 2. Monosaccharide analysis of B. thailandensis E555:: wbiI (pKnock-KmR) CPS by HPAE-PAD on Dionex Carbopac PA 20 column. The bottom trace shows the ion chromatogram
of CPC hydrolysis products and the top one is the same sample spiked with 25 mM 6-deoxy-D-manno-heptose standard. Peaks correspond to (A) e unidentified sugar, (B)-6-deoxy-D-
manno-heptose, and (C) e mannose. The analysis was performed on Dionex Carbopac PA 20 column (3  150 mm) at 0.25 mL/min in 8 mM NaOH at 25 C.
Fig. 3. Survival of BALB/c mice vaccinated with CPS-TetHc (acetylated and deacetylated
CPS), TetHc and alum followed by challenge with 1.17  105 CFU via the IP route of
B. pseudomallei K96243 (approximately 157 x median lethal doses (MLDs)). Mice were
vaccinated three times in two-week intervals prior to challenge. Vaccination with
acetylated CPS conjugate offered significantly greater protection than the deacetylated
CPS conjugate [p ¼ 0.0015 Log-Rank (Mantel Cox test [35])]. The deacetylated CPS-
TetHc conjugate did not offer any significantly greater protection than adjuvant or
TetHc alone [p ¼ 0.1694 and p ¼ 0.0872 Log-Rank, respectively (Mantel Cox test)].
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reasons the development of medical countermeasures against
these organisms is a priority. The manno-heptose-based CPS
expressed by B. pseudomallei and B. mallei has shown to be partially
protective in animal models of melioidosis, as have anti-CPS
monoclonal antibodies in passive transfer studies [13,14]. As
B. pseudomallei and B. mallei are classified by the Advisory Com-
mittee on Dangerous Pathogens (ACDP) as hazard group 3 patho-
gens, extraction of CPS in containment level 3 laboratories is
required: this is expensive and time consuming, although several
studies have described the extraction of CPS from non-pathogenic,select-agent excluded strains of B. pseudomallei [16,17]. Identifica-
tion of B. thailandensis E555 by Sim et al. [23], which expresses a
B. pseudomallei-like CPS provides an opportunity for a less expen-
sive, quicker route of CPS extraction and purification given the
lower levels of containment required for B. thailandensis E555. In
this study, we have shown through the use of NMR and mono-
saccharide analysis of hydrolysed polysaccharide that at a chemical
level, the capsular polysaccharide produced from B. thailandensis
E555 is essentially identical to that from the pathogenic Bur-
kholderia species B. pseudomallei. Furthermore, B. thailandensis
E555 also expresses the a-1,3 mannan found in its pathogenic rel-
atives. Recognition of CPS extracted from B. thailandensis E555 with
a monoclonal antibody raised against B. pseudomallei confirms
previous work by Sim et al. [23] and infers that both poly-
saccharides have an epitope of similar structure. The implications
of this finding mean that capsular polysaccharide can now be
extracted from B. thailandensis E555, a naturally avirulent bacte-
rium, which should reduce the cost of obtaining this polysaccharide
and may also make licensure easier than the use of hazard group 3
bacteria, or select-agent excluded strains of B. pseudomallei where
reversion to virulence is possible. The purity of CPS extracted from
B. thailandensis E555 was >90% and similar to the reported purity of
CPS extracted from Bp82 [16]. CPS yields from B. thailandensis E555
varied between 0.5 and 18 mg per litre of bacterial culture, which is
a wider range than the 10e15 mg per litre of culture reported from
Bp82 [16]. This may be due to slight procedural differences in the
extraction method rather than a difference in CPS expression be-
tween these two species. This laboratory has not extracted CPS
from B. pseudomallei and so a true comparison has not been made.
NMR analysis of B. thailandensis E555 extracted CPS shows that
the sample is approximately 90% 6-deoxy-manno-heptose and 10%
Fig. 4. ELISA analysis of acetylated and deacetylated CPS-specific IgG and IgM immune responses following vaccination with CPS conjugate vaccines. Mice were vaccinated with
native CPS-TetHc or deacetylated CPS-TetHc three times at 2-week intervals. Serum was obtained from mice 14 days after the third vaccination, and titres of IgG and IgM specific for
CPS or deacetylated CPS were determined by ELISA. Individual symbols represent a single immunised mouse. Significance was determined by unpaired t-test. LOD, limit of
detection.
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produced by B. pseudomallei than B. mallei, where for the latter the
ratio is approximately 43:57,9 indicating that B. thailandensis could
be more suitable as a proxy for B. pseudomallei than B. mallei. This is
also supported by Sim et al. [23], where PCR analysis with oligo-
nucleotide primers against six B. pseudomallei CPS genes (BPSL2791
to BPSL2797) were amplified in B. thailandensis E555. DNA
sequencing of the PCR products confirmed nucleotide similarities
of at least 92% to the CPS genes of B. pseudomallei K96243.
A solution to utilising native CPS as a melioidosis/glanders
vaccine antigen may lie in producing the polysaccharide, or frag-
ments thereof, by chemical synthesis or alternatively, naturally
occurring CPS extracted from non-pathogenic B. thailandensis could
be fragmented into minimal antigenic units (vide infra). This would
facilitate progress of the antigen through the regulatory process,
given that the vaccine candidate would be highly defined and
would not originate from the pathogen. In addition, set chain
lengths would lower the cost of production by increasing the
number of doses per mg of CPS based on the results of a cost-
benefit analysis commissioned by Dstl (unpublished). However,
yields of CPS following sizing and the final vaccine carbohydrate
content would have to be considered as optimal chain length and
CPS content per dose is currently unknown.
In spite of the huge progresses achieved in the chemical syn-
thesis of CPS fragments [24,25], the CPS molecule still represents a
challenge for carbohydrate chemistry, given the ambiguity sur-
rounding whether the a-1,3-mannan and 6-deoxy-D-manno-hep-
tose-based glycans are part of the same chain or are closely
associated chains that are difficult to separate; in addition, the b-
manno configuration also presents a challenge, particularly given
the presence of the 2-O-acetyl group. As recently reported by
Marchetti et al., [26] the acetyl group is required for 3C5 mono-
clonal antibody recognition of the molecule, although this study
did not determine whether the acetyl group was important for
achieving immune protection. In the current study, we found that a
panel of four anti-CPS monoclonal antibodies (DSTL187, 188, 189,
190) have no binding affinity for deacetylated CPS, which supports
the work by Marchetti et al. [26] and also demonstrates that these
antibodies do not bind the a-1,3-mannan which is present in these
samples.Whilst the acetyl group is demonstrably important for antibody
recognition, extrapolating this finding to protection against bacte-
rial challenge is difficult on this basis alone and does not address
the importance of potential antibodies raised against the CPS
backbone. In the present study, we have shown that the acetyl
moiety is essential for protection in an animal model of melioi-
dosis: CPS conjugated to the carrier protein TetHc provided signif-
icantly greater protection in vaccinated mice than a deacetylated
CPS conjugate. Furthermore, vaccination with the deacetylated CPS
conjugate offered no greater protection to bacterial challenge than
vaccination with adjuvant alone. Antibody analysis of sera from
mice vaccinated with the acetylated CPS conjugate showed mini-
mal cross-reactivity to purified de-acetylated CPS, which suggests
that the acetyl group is an integral part of an immunodominant
epitope. The lack of an IgM antibody response to deacetylated CPS
above the assay limit of detection, which was seen for CPS in this
work, also suggests that the deacetylated CPS is less immunogenic.
The essentiality of the CPS 2-OAc group for immune protection
presents challenges for fragmenting this large (>200 kDa, as judged
by PAGE) [36] polysaccharide into efficacious fragments. Both acid-
or base-catalysed polysaccharide fragmentation is associated with
concomitant de-O-acetylation (unpublished observations).
In summary, the use of capsular polysaccharide from Bur-
kholderia species as a vaccine against melioidosis and glanders re-
mains a tangible prospect. This study presents clear evidence that
B. thailandensis E555 extracted CPS can be used as a substitute
vaccine candidate to CPS from pathogenic species. We have shown
that the acetyl group of CPS forms an immunodominant, protective,
epitope which is an important finding for chemical efforts to pro-
duce synthetic CPS and also places limitations on the methods that
can be employed to fragment native CPS polysaccharide.4. Materials and methods
4.1. Bacterial growth and CPS isolation
The O-polysaccharide-deficient mutant of B. thailandensis E555
harbouring a kanamycin-resistancemarked, in-frame deletion of its
wbiI gene (B. thailandensis E555:: wbiI (pKnock-KmR)) [37] was
grown in 2 L of LB broth overnight at 37 C with shaking. Loss of O-
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western immunoblot analysis, with bacterial stocks maintained in
35% (v/v) glycerol suspensions at 80 C.
The CPS was extracted via a modified hot phenol method and
purified as described previously [9,38]. Briefly, the overnight cul-
ture was added in equal parts (v/v) to 90% (w/v) phenol and heated
to 80 C. The phenol was dialysed against distilled water using
Spectra/Por 6e8K MWCO dialysis membrane and the resulting cell
debris removed by centrifugation (10 min at 11,900g). The sam-
ples were then enzymatically digested with 50 mg/mL DNAse and
RNAse (Sigma) at 37 C for 2 h and then 50 mg/mL proteinase K
(Sigma) at 60 C for 3 h. The sample was then centrifuged at
11,900g for 40 min and the CPS isolated from the supernatant as
precipitated gel following ultracentrifugation at 100,000g for 6 h.
The gel pellet was re-suspended in ultrapure water and lyophilised
to concentrate. Rough LPS contaminants were then removed by
acid hydrolysis with 2% (v/v) acetic acid at 100 C for 2 h. The
sample was centrifuged at 11,900g for 40 min and the superna-
tants lyophilised to concentrate. The samples were then recon-
stituted at 20 mg/mL in ultrapure water and loaded onto a
Sephadex G-50 column (40 cm  2.6 cm). The purified CPS was
eluted isocratically in ultrapure water at a rate of 4 mL/min. The
fractions were analysed for carbohydrate using the phenol-
sulphuric acid method [39] with the appropriate fractions com-
bined and lyophilised.
CPS from B. pseudomallei 1026b for use as a reference in NMR
analysis was kindly provided by Associate Professor P. Brett from
the University of Nevada, Reno School of Medicine [9].
4.2. 1H and 13C NMR spectroscopy
The lyophilised CPS samples were reconstituted by dissolving in
700 mL D2O and NMR spectra were recorded with a Bruker Avance
III HD 400 MHz spectrometer operating at 400 MHz (1H) or
100.6 MHz (13C). Assignments were made with the aid of homo-
nuclear (COSY, NOESY) and heteronuclear (HSQC) two dimensional
correlation spectroscopy.
4.3. Polysaccharide hydrolysis with strong acid
A solution of polysaccharide (20 mL of a 3mg/mL solution inMQ-
H2O) was added to a screw cap reaction vial containing trifluoro-
acetic acid (30 mL in 150 mL of MQ-H2O). The vial was sealed and
heated to 100 C for 4 h. The reaction was stopped and the solution
was concentrated in vacuo using a SpeedVac® evaporation centri-
fuge (Thermo scientific). The polysaccharide was reconstituted in
MQ-H2O (300 mL), vortexed for 30 s and centrifuged for 5 min
(14,000g).
4.4. Monosaccharide analysis by HPAEC-PAD chromatography
Polysaccharide hydroxylates (10 mL) were injected onto a Dio-
nex® ICS-5000® HPAEC-PAD system and the monosaccharide
analysis was done using an 8 mM NaOH (Fisher® HPLC grade)
isocratic gradient (0.25 mL/min) for 40 min followed by a 6 min
wash step (100 mM NaOH) and a 15 min re-equilibration step.
Detection was achieved using pulsed amperometric detection
(PAD). Spiking experiments for identification of 6-deoxy-manno-
heptopyranose and D-mannopyranose were performed on a
monosaccharide by monosaccharide basis. This was due to the
impact of the addition of a monosaccharide on the retention times
of the monosaccharide mixture. The polysaccharide hydroxylate
samples were supplemented with monosaccharide standards (10/
25 mM final concentration) and injected onto the column (10 mL).4.5. Deacetylated CPS production
A sample of CPS (3 mg) in a glass sample vial was dissolved in
H2O (0.4 mL), conc. aqueous NH3 (0.2 mL) was added and the vial
was sealed and then heated at 50 C for 2 h. The sample was sub-
sequently freeze-dried and analysed by NMR. The disappearance of
CPS OAc peak was observed within 80 min.4.6. Generation of biotinylated monoclonal antibody DSTL189
DSTL189 antibody was diluted to 1 mg/mL in PBS. Using a sy-
ringe and needle, 1 mL of dimethylformamide (DMF) was intro-
duced into a vial of biotin-N-Hydroxysulfosuccinimide (NHS) ester
(Molecular Devices Corp.) and mixed until the label had completely
dissolved. The dissolved label was removed using the syringe and
introduced into a 1.5 mL Eppendorf tube and then placed in a foil
wrapper to prevent UV degradation of the label. 10.8 mL of biotin-
NHS label was then added to 1 mL of antibody solution and
mixed thoroughly before incubating at room temperature for 2 h in
the dark to achieve a molar coupling ration of 10. During this in-
cubation, a PD-10 column (GE Healthcare) was equilibrated with
25mL of PBS. A further 1e2mL of PBS was added to the column and
the bottom of the column capped (to prevent the upper disc from
drying out over the remainder of the incubation period). Once in-
cubation was complete, the cap was removed from the PD-10 col-
umn for the PBS to drain through. The 1 mL reaction volume was
added to the columns, allowed to drain through and 1.25 mL of PBS
added to each column to stop the reaction. Using graduated
Eppendorfs to collect fractions, 3 mL of PBS was added to the col-
umn. The first 0.75 mL was collected in the first Eppendorf, 1.5 mL
in the second Eppendorf and the remaining 0.75 mL in the third
Eppendorf. This was repeated for the remaining reactions. The
absorbance of the fractions was measured on a UV-VIS spectro-
photometer at 280 nm and 362 nm. The labelled antibodies were
stored at 70 C until use.4.7. Antibody analysis of purified CPS extracted from B.
thailandensis E555:: wbiI (pKnock-KmR) and B. pseudomallei 1026b
A 96-well microtiter plate was coated overnight at 4 C with 100
mL/well of purified monoclonal antibody (DSTL189) diluted to 5 mg/
mL in PBS (Dulbecco's PBS 1 x without CaCl2, MgCl2). During all
incubations, the microtiter plates were covered with plate sealers.
Each well was washed three times with PBS-Tween 20 (0.05%) and
blocked with 200 mL of PBS containing 2% (w/v) skimmed milk
powder (BLOTTO) for 1 h at 37 C. Purified CPS from B. thailandensis
E555:: wbiI (pKnock-KmR)) and B. pseudomallei 1026b was diluted
to an initial concentration of 10 mg/mL and serially diluted 1:3 in
100 mL aliquots on the plate. Following incubation for 1 h at 37 C,
each well was washed three times with PBS-Tween 20 (0.05%) and
100 mL/well of biotinylated DSTL189 antibody diluted in BLOTTO to
5 mg/mL was added. The plate was incubated for 1 h at 37 C and
each well then washed three times with PBS-Tween 20 (0.05%). A
1:1000 dilution of streptavidin peroxidase (Sigma) in 2% BLOTTO
was then added and incubated at 37 C for 1 h. Each well was
washed six times with PBS-Tween 20 (0.05%) and bound conjugate
detected with 100 mL/well of enzyme substrate (55 mg 2,20-azino-
bis(ethylbenzthiazoline-6-sulphonic acid) in 56 mL of 0.1 M citric
acid, 44 mL of Na2HPO4 and 100 mL 30% (w/w) hydrogen peroxide,
with incubation at room temperature for 15 min prior to optical
density measurement at 414 nm.
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extracted from B. thailandensis E555::wbiI (pKnock-KmR)
A 96-well microtiter plate was coated overnight at 4 C with 100
mL/well of B. thailandensis E555::wbiI (pKnock-KmR) purified CPS or
B. thailandensis E555::wbiI (pKnock-KmR) purified deacetylated
CPS at 10 mg/mL in PBS (Dulbecco's PBS 1 x, without CaCl2, MgCl2).
During all incubations, the microtiter plates were covered with
plate sealers. Eachwell waswashed three times with PBS-Tween 20
(0.05%) and blocked with 200 mL of PBS containing 2% (w/v)
skimmed milk powder (BLOTTO) for 1 h at 37 C. Primary anti-
bodies (DSTL187, 188, 189, 190)13 were diluted to 5 mg/mL in 2%
BLOTTO and 100 mL was added to the plate in duplicate. The plate
was then incubated for 1 h at 37 C and each well washed three
times with PBS-Tween 20 (0.05%). Goat anti-mouse IgG-HRP con-
jugate (Biorad) was diluted 1:2000 in 2% BLOTTO, 100 mL added to
each well and the plate incubated at 37 C for 1 h. Each well was
washed six times with PBS-Tween 20 (0.05%) and bound conjugate
detected with 100 mL/well of enzyme substrate (55 mg 2,20-azino-
bis(ethylbenzthiazoline-6-sulphonic acid)) in 56 mL of 0.1 M citric
acid, 44 mL of Na2HPO4 and 100 mL 30% (w/w) hydrogen peroxide,
with incubation at room temperature for 20 min prior to optical
density measurement at 414 nm.4.9. TetHc production
TetHc production was performed as previously reported [40].
Briefly, recombinant tetanus toxin Hc fragment was recovered from
E. coli BL21 (pKS1-TetHc), kindly supplied by Dr N. Fairweather [41].
The recombinant His-tagged proteinwas eluted with up to 500mM
imidazole using HisTrap Columns (GE Healthcare) on an ATKA FPLC
(GE Healthcare). Protein purity was assessed by Coomassie stained
SDS PAGE gels (Expedeon) and protein concentration by BCA assay
(Pierce).4.10. CPS conjugation to TetHc
CPS and TetHc conjugationwas performed as detailed previously
[16,17]. Briefly, purified CPS was solubilised at 5 mg/mL in PBS
(Sigma) and sodium meta-periodate (Alpha Aesar) was added to a
final 30 mM concentration. The mixture was gently stirred at room
temperature for 40 min and afterwards, excess oxidising agent was
removed by dialysis (GeBAflex-tube maxi). To the dialysed poly-
saccharide solution, TetHc protein was added to a final concentra-
tion of 5 mg/mL in PBS (Sigma). Sodium cyanoborohydride (Sigma:
1 M NaBH3CN in 10 mM NaOH) was then added at 10 mL per mL of
conjugation mixture and then stirred at room temperature for 4
days. Following this, a further 10 mL of sodium borohydride (Sigma:
1 M NaBH4 in 10 mM NaOH) was added to each mL of conjugation
mixture and stirring was continued at room temperature for
40 min. The conjugate reactions were then dialysed against
distilled water (GeBAflex-tube maxi) and analysed by SDS-PAGE
(12%, Expedeon) and western blot using anti-CPS monoclonal
antibody DSTL189. The resulting products were then re-dissolved
in ultrapure water and stored at 20 C.4.11. Conjugate analysis
CPS concentration was determined by the phenol-sulfuric acid
assay [39] using 6-deoxy-manno-heptose to generate a standard
curve and analysed against a known concentration of CPS. TetHc
concentration was determined by the BCA protein assay (Pierce).4.12. Animal challenge
Groups of 10 BALB/c female mice between 6 and 8 weeks old
(Charles River UK) were acclimatised for two weeks prior to
experimental start and vaccinated via the intra-muscular (IM) route
on Day 0 with either B. thailandensis E555 CPS conjugated to TetHc
or deacetylated B. thailandensis E555 CPS conjugated to TetHc, at a
concentration of 10 mg CPS permouse re-constituted in PBS and 18%
v/v Alum (Invitrogen). Mice vaccinated with the acetylated CPS
received 6 mg of TetHc and the mice that received the deacetylated
CPS: 3.3 mg TetHc. Groups of 5 control mice were given adjuvant or
TetHc only (6 mg per mouse per dose). Vaccine boosts were given on
days 14 and 28 and the mice were challenged via the intra-
peritoneal (IP) route with 0.1 mL of B. pseudomallei K96243 at
1.17  105 cfu per mouse on day 63 [157 x median lethal dose
(MLD)]. We previously determined the MLD in the BALB/c mouse
model to be 744 CFU by the IP route [17]. The mice were observed
twice daily for a period of 35 days after challenge when surviving
mice were culled. All mice were tail-bled 2 weeks post-vaccination.
Survival data was analysed with GraphPad Prism and by the Log-
Rank (Mantel-Cox) test [35]. All animal work was carried out ac-
cording to the Animal (Scientific Procedures) Act 1986 and
following challenge, the mice were handled within a containment
level 3 half-suit isolator.
4.13. Antibody analysis of animal sera
ELISAs were performed on sera collected 2 weeks after the third
vaccination. 96 well plates were coated with either purified CPS or
deacetylated CPS at 10 mg/mL in PBS (Dulbecco's PBS 1 x, without
CaCl2, MgCl2) and incubated overnight at 4 C. Each well was
washed three times with PBS supplemented with 0.05% (v/v)
Tween-20 (Sigma). The wells were then blocked with 2% (w/v)
skimmed milk powder (Sigma) in PBS and incubated at 37 C for
1 h. Following three further washes with PBS-Tween, two-fold di-
lutions of the mouse serum samples in PBS supplemented with 2%
(w/v) skimmedmilk powder were made across the plate. To act as a
standard curve, one row of wells was coated with 5 mg/mL anti-fab
antibody (Sigma), incubated and washed as described above.
Appropriate isotype standards (Sigma) were diluted twofold across
the plate. Also included into separate wells was serum from PBS
and TetHc vaccinated control mice as negative controls. The plate
was incubated for a further 1 h at 37 C and washed three times in
PBS-Tween. A 1:2000 dilution of isotype specific goat anti-mouse
horseradish peroxidase conjugate (Biorad) in PBS supplemented
with 2% (w/v) milk powder was added to each well and the plate
incubated at 37 C for 1 h. Following six washes in PBS-Tween,
100 mL of tetramethylbenzidine (KPL) substrate was added to
each well according to the manufacturer's instructions, and incu-
bated at room temperature for 20 min prior to measuring the
absorbance at 620 nm.
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